IE 11 is not supported. For an optimal experience visit our site on another browser.

Athersys to Host Third Quarter Financial Results Call

CLEVELAND, Oct. 14, 2010 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX) today announced it will release its third quarter financial results at approximately 4:00 PM Eastern Time (ET) on Monday, November 8, 2010, and host a conference call shortly thereafter at 4:30 PM ET to review the results. Gil Van Bokkelen, Chairman and Chief Executive Officer, and William (B.J.) Lehmann, President and Chief Operating Officer, will host the call.
/ Source: GlobeNewswire

CLEVELAND, Oct. 14, 2010 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX) today announced it will release its third quarter financial results at approximately 4:00 PM Eastern Time (ET) on Monday, November 8, 2010, and host a conference call shortly thereafter at 4:30 PM ET to review the results. Gil Van Bokkelen, Chairman and Chief Executive Officer, and William (B.J.) Lehmann, President and Chief Operating Officer, will host the call.

Investors and other interested parties are invited to listen to the conference call by dialing 800-273-1254 in the U.S. and Canada, 973-638-3440 from abroad, or via a live Internet broadcast at the Company's website at , under the Investors section.

A replay will be available for on-demand listening shortly after the completion of the call until 11:59 PM ET on November 22, 2010, at the aforementioned URL, or by dialing 800-642-1687 in the U.S. and Canada, or 706-645-9291 from abroad, and entering access code 18341603.

About Athersys

Athersys is a clinical stage biopharmaceutical company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The Company is developing MultiStem®, a patented, adult-derived "off-the-shelf" stem cell product platform for multiple disease indications, including damage caused by myocardial infarction, bone marrow transplantation and oncology treatment support, ischemic stroke, and inflammatory bowel disease. The Company is also developing a portfolio of other therapeutic programs, including orally active pharmaceutical product candidates for the treatment of metabolic and central nervous system disorders, utilizing proprietary technologies, including Random Activation of Gene Expression (RAGE®). Athersys has forged several key strategic alliances and collaborations with leading pharmaceutical and biotechnology companies, as well as world-renowned research institutions in the United States and Europe to further develop its platform and products. More information is available at .

The Athersys, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=4548

CONTACT: Athersys, Inc. William (B.J.) Lehmann, J.D., President and Chief Operating Officer (216) 431-9900 bjlehmann@athersys.com In-Site Communications Investor Relations: Lisa M. Wilson (917) 543-9932 lwilson@insitecony.com Pure Communications, Inc. Media Relations: Dan Budwick 973-271-6085 dan@purecommunicationsinc.com